Junshi Biosciences and Coherus Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
– FDA has set a target action date of December 23, 2022 for the toripalimab BLA – – Toripalimab will be the first and only immuno-oncology agent for NPC in U.S., if approved – SHANGHAI, China and REDWOOD CITY, Calif., July 06, 2022 (GLOBE NEWSWIRE via SEAPRWire.com) — Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; […]